We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Ovarian Cancer Test Exhibits Exceptional Accuracy

By LabMedica International staff writers
Posted on 23 Aug 2010
A new technique correctly identified women with ovarian cancer in 100% of the patients tested using mass spectrometry analysis of one drop of blood.

The measurement step in the test used 200 μL of blood serum, which is vaporized by hot helium plasma. As the molecules from the serum become electrically charged, a mass spectrometer is used to measure their relative abundance.

The test looks at metabolites in the serum. Sera were obtained from 44 women with ovarian cancer, and 50 women with either benign conditions or were healthy. The sera were analyzed by high throughput ambient ionization technique for mass spectrometry. This gives direct real time analysis of the profile relative metabolites levels in the sera. The profiles were input to a customized functional support vector machine–based machine-learning algorithm for diagnostic classification. Performance was evaluated through a 64-30 split validation test and with a stringent series of leave-one-out cross-validations.

The scientists at Georgia Institute of Technology, (Atlanta, GA, USA), reported that the assay did extremely well in initial tests involving 94 subjects. In addition to being able to generate results using only a drop of blood serum, the test proved to be 100% accurate in distinguishing sera from women with ovarian cancer from normal controls. In addition, it registered neither a single false positive nor a false negative.

John McDonald, Ph.D. the Chief Research Scientist at Georgia Tech., said, "Because ovarian cancer is a disease of relatively low prevalence, it is essential that tests for it be extremely accurate. We believe we may have developed such a test." The results of the study were published online in July 2010 in the journal Cancer Epidemiology, Biomarkers, & Prevention Research. In addition to having a relatively low prevalence, ovarian cancer is also asymptomatic in the early stages. Therefore, if further testing confirms the ability to accurately detect ovarian cancer by analyzing metabolites in the serum of women, doctors will be able detect the disease early and save many lives.

Related Links:
Georgia Institute of Technology



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
PSA Assay
CanAg PSA EIA

Latest Clinical Chem. News

New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
23 Aug 2010  |   Clinical Chem.

New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
23 Aug 2010  |   Clinical Chem.

Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
23 Aug 2010  |   Clinical Chem.



PURITAN MEDICAL